Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study-Reference-Cited by-同舟云学术

Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study

Published:2017-07-19 Issue:12 Volume:56 Page:1769-1775
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Gelderblom Hans¹,Judson Ian R.²,Benson Charlotte²,Merimsky Ofer³,Grignani Giovanni⁴,Katz Daniela⁵,Freivogel Klaus W.⁶,Stein Dara⁷,Jobanputra Minesh⁸,Mungul Arron⁹,Manson Stephanie C.¹⁰,Sanfilippo Roberta¹¹

Affiliation:

1. Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands;

2. Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, UK;

3. Unit of Bone and Soft Tissue Oncology, Tel-Aviv Sourasky Medical Center and Tel-Aviv University Sackler School of Medicine, Tel-Aviv, Israel;

4. Divisione Oncologia Medica, Candiolo Cancer Institute – FPO I.R.C.C.S., Candiolo, Italy;

5. Hadassah-Hebrew University Medical Center, Jerusalem, Israel;

6. United BioSource (Germany) GmbH, Loerrach, Germany;

7. United BioSource Corporation, Quebec, Canada;

8. bluebird bio, London, UK;

9. Bristol-Myers Squibb, Uxbridge, UK;

10. Novartis Oncology, East Hanover, NJ, USA;

11. Adult Mesenchymal Tumor Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy